You invested in a cutting-edge biotechnology company working to commercialize a material hailed as the “Holy Grail of textiles,” yet it’s clear you don’t fully grasp the complexities, challenges, and unpredictable nature of pioneering something that’s never been done before. Instead of understanding the iterative progress required in biotech, you cling to the oversimplified buzzphrase ‘credibility issue’ every time a timeline shifts. You’ve admitted Kim isn’t lying, isn’t untrustworthy, and that you still see the potential for a massive payoff—yet you continue to chant ‘credibility issue’ like it’s some protective shield against admitting your lack of understanding.
The reality is, credibility isn’t about hitting every estimate—it’s about making measurable progress. And KBLB is progressing: Bam-1 hybrids are producing, scalability is improving, and commercialization is closer than ever. If Kim truly lacked credibility, you—and your "not the only one" crowd—wouldn’t still be here. Your frustration doesn’t stem from Kim’s leadership; it stems from your own misunderstanding of what you invested in. You’re hedging your emotional bets, hoping for success while preparing to claim “I told you so” if there’s a stumble. That’s not insight—it’s self-preservation. The real credibility issue here isn’t with Kim Thompson—it’s with you. FACT!
Bullish
Market Data 
Markets 
AI
